Safety and Effectiveness of Perospirone in Comparison to Risperidone for Treatment of Delirium in Patients with Advanced Cancer: A Multicenter Prospective Observational Study in Real-World Psycho-Oncology Settings

被引:1
作者
Inoue, Shinichiro [1 ]
Maeda, Isseki [3 ]
Ogawa, Asao [4 ]
Yoshiuchi, Kazuhiro [5 ]
Terada, Seishi [2 ]
Yamada, Norihito [2 ]
机构
[1] Okayama Univ Hosp, Dept Neuropsychiat, Okayama 7008558, Japan
[2] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Neuropsychiat, Okayama 7008558, Japan
[3] Senri Chuo Hosp, Dept Palliat Care, Toyonaka, Osaka 5600082, Japan
[4] Natl Canc Ctr Hosp East, Dept Psychooncol Serv, Kashiwa, Chiba 2778577, Japan
[5] Univ Tokyo, Grad Sch Med, Dept Stress Sci & Psychosomat Med, Bunkyo Ku, Tokyo 1138655, Japan
关键词
delirium; cancer; perospirone; risperidone; PALLIATIVE CARE; RATING-SCALE; RISK; RECOMMENDATIONS; HALOPERIDOL; REVISED-98; ISSUES;
D O I
暂无
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The clinical benefit of perospirone for treatment of delirium in patients with advanced cancer is not sufficiently clear. The objective of this study was to compare the safety and effectiveness of perospirone to those of risperidone for the treatment of delirium in patients with advanced cancer. This is a secondary analysis of a multicenter prospective observational study in nine psycho-oncology consultation services in Japan. The study used the Delirium Rating Scale (DRS) Revised-98 to measure effectiveness and the CTCAE (Common Terminology Criteria for Adverse Events) version 4 to assess safety. Data from 16 patients who received perospirone and 53 patients who received risperidone were analyzed. The mean age was 70 years in the perospirone group and 73 years in the risperidone group. Both groups showed a significant decrease in the total score of DRS-R-98 after three days of treatment (perospirone: 11.7 (7.9-15.4) to 7.0 (3.3-10.7), difference -4.7, effect size = 0.72, p = 0.003; risperidone: 15.5 (13.6-17.4) to 12.2 (10.1-14.2), difference -3.3, effect size= 0.55, p = 0.00). The risperidone group showed significant improvements in sleep-wake cycle disturbance, orientation, attention, and visuospatial ability. In the perospirone group, there was a significant improvement of sleep-wake cycle disturbance. The median daily dose of perospirone was 4 mg/day. There were fewer episodes of somnolence as an adverse event in the perospirone group. Low-dose perospirone was thus found to be effective for the treatment of delirium in patients with advanced cancer and may be associated with fewer episodes of over-sedation as an adverse event.
引用
收藏
页码:195 / 202
页数:8
相关论文
共 29 条
[1]   Efficacy of Oral Risperidone, Haloperidol, or Placebo for Symptoms of Delirium Among Patients in Palliative Care A Randomized Clinical Trial [J].
Agar, Meera R. ;
Lawlor, Peter G. ;
Quinn, Stephen ;
Draper, Brian ;
Caplan, Gideon A. ;
Rowett, Debra ;
Sanderson, Christine ;
Hardy, Janet ;
Le, Brian ;
Eckermann, Simon ;
McCaffrey, Nicola ;
Devilee, Linda ;
Fazekas, Belinda ;
Hill, Mark ;
Currow, David C. .
JAMA INTERNAL MEDICINE, 2017, 177 (01) :34-42
[2]  
[Anonymous], 2010, DEL PREV DIAGN MAN
[3]  
[Anonymous], 2013, DIAGN STAT MAN MENT, DOI DOI 10.1176/APPI.BOOKS.9780890425596
[4]   A 10-year cohort study of the burden and risk of in-hospital falls and fractures using routinely collected hospital data [J].
Brand, C. A. ;
Sundararajan, V. .
QUALITY & SAFETY IN HEALTH CARE, 2010, 19 (06) :e51
[5]  
Breitbart W, 1996, AM J PSYCHIAT, V153, P231
[6]   Treating an Established Episode of Delirium in Palliative Care: Expert Opinion and Review of the Current Evidence Base With Recommendations for Future Development [J].
Bush, Shirley H. ;
Kanji, Salmaan ;
Pereira, Jose L. ;
Davis, Daniel H. J. ;
Currow, David C. ;
Meagher, David J. ;
Rabheru, Kiran ;
Wright, David Kenneth ;
Bruera, Eduardo ;
Agar, Meera ;
Hartwick, Michael ;
Gagnon, Pierre R. ;
Gagnon, Bruno ;
Breitbart, William ;
Regnier, Laura ;
Lawlor, Peter G. .
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2014, 48 (02) :231-248
[7]  
de Paulis Tomas, 2002, Curr Opin Investig Drugs, V3, P121
[8]   Psychoactive medications and risk of delirium in hospitalized cancer patients [J].
Gaudreau, JD ;
Gagnon, P ;
Harel, F ;
Roy, MA ;
Tremblay, A .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (27) :6712-6718
[9]   Current topics in tardive dyskinesia in Japan [J].
Inada, T ;
Yagi, G .
PSYCHIATRY AND CLINICAL NEUROSCIENCES, 1995, 49 (5-6) :239-244
[10]  
Kato M, 2010, PSYCHOSOMATICS, V51, P425, DOI 10.1176/appi.psy.51.5.425